3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
2
Active not recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
3
Breast
2
Tumor-Agnostic
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
2
Interventions
Trastuzumab
379
Paclitaxel
369
Cyclophosphamide
338
Docetaxel
314
Capecitabine
198
Doxorubicin
196
Letrozole
184
Tamoxifen
154
Carboplatin
153
Fulvestrant
136
Bevacizumab
129
Anastrozole
120
exemestane
119
Lapatinib
117
Epirubicin
116
Gemcitabine
112
Radiotherapy
107
palbociclib
94
Exercise
87
Fluorouracil
83
Vinorelbine
82
Surveys and Questionnaires
81
pertuzumab
77
Albumin-Bound Paclitaxel
76
Filgrastim
71
130-nm albumin-bound paclitaxel
64
pembrolizumab
63
Everolimus
59
Cisplatin
59
eribulin
58
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
AZD4547
×
Breast
×
Clear all
NCT01791985
2022-08-22
RADICAL
Imperial College London
Phase 1/2
Completed
52 enrolled
17 charts
NCT01202591
2016-02-11
GLOW
AstraZeneca
Phase 1/2
Completed
127 enrolled
8 charts